We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ortho Exhibits High Quality, Accurate and Cost Effective COVID19 Testing Solutions at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Illustration
Illustration

Ortho Clinical Diagnostics (Raritan, NJ, USA) exhibited its range of high quality, accurate and cost effective COVID19 testing solutions at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo held at the Georgia World Congress Center in Atlanta, September 26-30.

Over the span of the four day event, attendees connected with global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine.

Ortho has been at the forefront of developing high quality, accurate, cost effective COVID19 testing solutions that run at high volumes. At AACC 2021, Ortho demonstrated its high-throughput testing solutions for SARS-CoV-2 infection, antibody detection and antigen detection. These included the high-throughput, highly accurate VITROS SARS-CoV-2 antigen test that detects acute infection of SARS-CoV-2. The test delivers fast, high-volume testing for active infection with excellent specificity and sensitivity, making it a viable alternative to PCR testing.

In addition, Ortho highlighted its three qualitative antibody tests, including the VITROS COVID-19 Total and IgG antibody assays that provide highly accurate and reliable detection of SARS-CoV-2 antibodies to help clinicians and researchers understand immune response; and its VITROS Anti-SARS-CoV-2 Total N antibody test that is designed to capture total antibodies to the nucleocapsid protein. Also on display at AACC 2021 was the VITROS Anti-SARS-CoV-2 IgG quantitative test that helps labs to quantify the level of COVID-19 antibodies for patients and individuals in their communities. The VITROS Anti-SARS-CoV-2 IgG quantitative test is the first quantitative test to receive U.S. Food and Drug Administration (FDA) EUA. Ortho also demonstrated its VITROS Performance Dashboard that allows labs to view productivity data from Ortho analyzers including: test volumes, positivity rates, quality and efficiency information to help make more informed decisions for the hospital and community.

Related Links:
Ortho Clinical Diagnostics 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Nutating Mixer
Enduro MiniMix

Print article
ADLM

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more